Trump’s prescription drug price cuts unlikely to hit Indian pharma exports significantly: Crisil Ratings

Crisil Ratings reports that President Trump's order to cut US drug prices will have a limited effect on Indian pharma. India's exports, mainly low-cost generics with thin margins, leave little room for price cuts. The order targets high-margin branded drugs, not generics. While API exports remain unaffected, contract manufacturing may see opportunities, though with potential margin pressure.